0001209191-23-037167.txt : 20230614
0001209191-23-037167.hdr.sgml : 20230614
20230614184050
ACCESSION NUMBER: 0001209191-23-037167
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230612
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McNeill Jonathan
CENTRAL INDEX KEY: 0001824673
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 231015518
MAIL ADDRESS:
STREET 1: C/O DYNE THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-12
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001824673
McNeill Jonathan
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD
WALTHAM
MA
02451
0
1
0
0
See Remarks
1
Common Stock
2023-06-12
4
S
0
1000
13.00
D
64391
D
Common Stock
2023-06-13
4
S
0
1259
12.43
D
63132
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.95 to $13.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
Includes 59,326 unvested RSUs.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
Senior Vice President of Business Development
/s/ Richard Scalzo, Attorney-in-Fact
2023-06-14